Journals / Cyprus Journal of Medical Sciences / 2020 / Cilt: 5 - Sayı: 1

Childhood and Adolescence Vitiligo: Clinicoepidemiological Profile and Its Impact on Quality of Life

Pages
41–46
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In clinical practice, it is important to remember that vitiligo is not only a cosmetic disorder; it may negatively affect multiple aspects of the patient’s QoL.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:BACKGROUND/AIMS Vitiligo is an acquired, idiopathic, generally progressive pigmentation disorder of an unknown etiology.
📊
Key Findings & Data:MATERIAL and METHODS Thirty-one vitiligo patients aged 5–16 years who visited the outpatient dermatology clinic were included in the study.
💡
Conclusion & Impact:In clinical practice, it is important to remember that vitiligo is not only a cosmetic disorder; it may negatively affect multiple aspects of the patient’s QoL.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

BACKGROUND/AIMS Vitiligo is an acquired, idiopathic, generally progressive pigmentation disorder of an unknown etiology. Vitiligo usually begins during childhood or adolescence. This study aimed to evaluate the clinical and demographic characteristics of this disease as well as understand its impact on patient quality of life (QoL). MATERIAL and METHODS Thirty-one vitiligo patients aged 5–16 years who visited the outpatient dermatology clinic were included in the study. The demographic information of all the patients was collected. A complete clinical examination was performed, and the disease-related features were recorded. Moreover, all the patients completed the children’s dermatology life quality index (CDLQI). RESULTS Of the 31 patients, 20 were girls (64.5%), and 11 were boys (35.5%). The mean patient age was 10.33±4.19 years. Vitiligo vulgaris was the most common (51.6%) clinical type of vitiligo. The most commonly involved areas were the trunk (54.9%), face (54.9%), and extremities (41.7%). In the study group, 32.3% of the patients (10 of 31) had an accompanying autoimmune disease. The median CDLQI score of the patient group was 6 (min–max: 0–22). There was a significant correlation between patient age and CDLQI score (r=0.369, p=0.041). CONCLUSION Vitiligo has a different clinicoepidemiological profile in children and adolescents. This disease significantly lowers the patient’s QoL. Our study found a significant correlation between patient age and CDLQI score. In clinical practice, it is important to remember that vitiligo is not only a cosmetic disorder; it may negatively affect multiple aspects of the patient’s QoL.

🔖

Cite This Article

KARAOSMANOĞLU, N., ÇETİNKAYA, P., İMREN, I. G., NALBANT, E. K., KARAASLAN, E. (2020). Childhood and Adolescence Vitiligo: Clinicoepidemiological Profile and Its Impact on Quality of Life. Cyprus Journal of Medical Sciences, Cilt: 5 - Sayı: 1, 41–46. https://ajindex.com/articles/148242

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Dertlioglu SB, Cicek D, Balci DD, Halisdemir N. Dermatology life quality index scores in children with vitiligo: comparison with atopic dermatitis and healthy control subjects. Int J Dermatol 2013; 52(1): 96-101. [CrossRef] 2. Kruger C, Panske A, Schallreuter KU. Disease-related behavioral patterns and experiences affect quality of life in children and adolescents with vitiligo. Int J Dermatol 2014; 53(1): 43-50. [CrossRef] 3. Jaisankar TJ, Baruah MC, Garg BR. Vitiligo in children. Int J Dermatol 1992; 31(9): 621-3. [CrossRef] 4. Lewis-Jones MS, Finlay AY. The Children’s Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol 1995; 132(6): 942-9. [CrossRef] 5. Balcı DD, Sangun O, Inandı T. Cross-validation of the Turkish version of the children’s dermatology life quality index. J Turk Acad Dermatol 2007; 1(4): 1-5. 6. Olsen JR, Gallacher J, Finlay AY, Piguet V, Francis NA. Quality of life impact of childhood skin conditions measured using the Children’s Dermatology Life Quality Index (CDLQI): a meta-analysis. Br J Dermatol 2016; 174(4): 853-61. [CrossRef] 7. Schwartz R, Sepulveda JE, Quintana T. [Possible role of psychological and environmental factors in the genesis of childhood vitiligo]. Rev Med Chil 2009; 137(1): 53-62. [CrossRef] 8. Agarwal S, Ramam M, Sharma VK, Khandpur S, Pal H, Pandey RM. A randomized placebo-controlled double-blind study of levamisole in the treatment of limited and slowly spreading vitiligo. Br J Dermatol 2005; 153(1): 163-6. [CrossRef] 9. Bilgic O, Bilgic A, Akis HK, Eskioglu F, Kilic EZ. Depression, anxiety and health-related quality of life in children and adolescents with vitiligo. Clin Exp Dermatol 2011; 36(4): 360-5. [CrossRef] 10. Njoo MD, Bos JD, Westerhof W. Treatment of generalized vitiligo in children with narrow-band (TL-01) UVB radiation therapy. J Am Acad Dermatol 2000; 42(2 Pt 1): 245-53. [CrossRef] 11. Silverberg JI, Silverberg NB. Quality of life impairment in children and adolescents with vitiligo. Pediatr Dermatol 2014; 31(3): 309-18. [CrossRef] 12. Kovacs SO. Vitiligo. J Am Acad Dermatol 1998; 38(5 Pt 1): 647-66; quiz 67-8. [CrossRef] 13. Halder RM. Childhood vitiligo. Clin Dermatol 1997; 15(6): 899-906. [CrossRef] 14. Halder RM, Grimes PE, Cowan CA, Enterline JA, Chakrabarti SG, Kenney JA, Jr. Childhood vitiligo. J Am Acad Dermatol 1987; 16(5 Pt 1): 948-54. [CrossRef] 15. Handa S, Dogra S. Epidemiology of childhood vitiligo: a study of 625 patients from north India. Ped